Genelux Corporation Common Stock

GNLX XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

130M

Short interest (May 15)

6.6%

Net Short (Jun 03 ): -0.1%

Borrow Fee

1.20%

↓ 24.5%

Available Shares

300K

↓ 17.3%

Price Chart

Company Overview

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001231457

Asset Type: CS

Market Data

Market Cap: $132,279,227

Employees: 26

Status: Active

Short Interest

Current Borrow Fee 1.20%

Range: 1.20% - 1.26%

Available Shares 300K

Range: 300K - 300K

Recent Changes

Fee Change: ↑ 0.3%

Available Change: ↓ 0.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime